Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JANUMET vs EMPAGLIFLOZIN; LINAGLIPTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that prolongs the activity of incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.
10 mg empagliflozin/5 mg linagliptin orally once daily.
Sitagliptin: 12.4 hours (terminal). Clinical context: supports once-daily dosing, but half-life increases in renal impairment. Metformin: 6.2 hours (terminal). Shorter half-life requires multiple daily dosing; prolonged in renal impairment.
Empagliflozin: ~12.4 h (supports once-daily dosing). Linagliptin: ~12 h (terminal half-life; long binding to DPP-4 allows once-daily dosing despite short half-life).
Sitagliptin is primarily excreted unchanged in urine via active tubular secretion, with minor metabolism via CYP3A4 and CYP2C8. Metformin is not metabolized and is excreted unchanged in urine by tubular secretion.
Empagliflozin is primarily metabolized via glucuronidation (UGT2B7, UGT1A3, UGT1A8, UGT1A9) with minor CYP450 involvement. Linagliptin is minimally metabolized; approximately 90% is excreted unchanged via enterohepatic system (biliary excretion) and renal elimination is negligible.
Sitagliptin: 87% renal (unchanged), 13% fecal (metabolites). Metformin: 90-100% renal (unchanged), <5% fecal.
Empagliflozin: ~54% renal (unchanged), ~41% fecal (primarily unchanged parent). Linagliptin: ~80% fecal (enterohepatic circulation), ~5% renal.
Sitagliptin: 38% (albumin). Metformin: negligible (<5%).
Empagliflozin: ~86.2% (primarily albumin). Linagliptin: 70-80% (concentration-dependent, saturable binding to DPP-4; also albumin).
Sitagliptin: 198 L (≈2.8 L/kg for 70 kg). Metformin: 654 L (≈9.3 L/kg for 70 kg). Clinical meaning: Metformin Vd indicates extensive tissue distribution, predominantly in gastrointestinal tissues and red blood cells.
Empagliflozin: Vd/F ~9.6 L (0.14 L/kg; extensive tissue distribution). Linagliptin: Vd ~1000 L (14 L/kg; large due to extensive tissue binding).
Sitagliptin: 87% (oral). Metformin: 50-60% (oral), variable with food.
Empagliflozin: oral bioavailability ~78% (high, unaffected by food). Linagliptin: oral bioavailability ~30% (food has no effect; low due to first-pass and saturable absorption).
Contraindicated if e GFR <30 m L/min/1.73 m2. e GFR 30-45: do not initiate; if already on therapy, reduce dose to 25 mg sitagliptin/500 mg metformin once daily. e GFR 45-60: maximum dose 50 mg sitagliptin/1000 mg metformin twice daily. Monitor renal function.
Contraindicated if e GFR < 30 m L/min/1.73 m². Not recommended if e GFR < 45 m L/min/1.73 m². No dose adjustment for e GFR ≥ 45 m L/min/1.73 m².
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) due to metformin component risk of lactic acidosis.
No dose adjustment required for mild, moderate, or severe hepatic impairment (Child-Pugh A, B, C).
Not approved for use in pediatric patients (<18 years). Safety and efficacy not established.
Safety and efficacy not established in pediatric patients.
Use with caution; monitor renal function closely. Initiate at lowest dose (25 mg sitagliptin/500 mg metformin) and titrate slowly. Avoid in patients aged ≥80 years unless normal renal function confirmed.
No dose adjustment based on age alone. Assess renal function; contraindicated if e GFR < 30 m L/min/1.73 m². Consider increased risk of volume depletion and hypotension in patients aged ≥75 years.
Lactic acidosis: Metformin hydrochloride can cause lactic acidosis, a rare but serious condition. If suspected, discontinue Janumet and treat promptly.
None
Lactic acidosis risk (sepsis, dehydration, hepatic impairment, alcohol abuse, unstable CHF, radiologic contrast studies),Pancreatitis (discontinue if suspected),Hypoglycemia (especially with sulfonylurea or insulin coadministration),Renal impairment (assess renal function before initiation and periodically; contraindicated if e GFR <30 m L/min/1.73 m²),Vitamin B12 deficiency (monitor levels with long-term metformin use),Hypersensitivity reactions (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome),Heart failure (monitor for signs; cardiovascular outcome trials showed no increased risk with saxagliptin, but caution with DPP-4 inhibitors)
Risk of pancreatitis (linagliptin),Risk of genital mycotic infections and urinary tract infections (empagliflozin),Risk of volume depletion, hypotension, and acute kidney injury (empagliflozin),Risk of ketoacidosis, including euglycemic ketoacidosis (empagliflozin),Risk of hypoglycemia when used with insulin or sulfonylureas,Risk of heart failure (linagliptin; postmarketing reports),Risk of bullous pemphigoid (DPP-4 inhibitors),Risk of severe and disabling arthralgia (DPP-4 inhibitors)
Severe renal impairment (e GFR <30 m L/min/1.73 m²),Acute or chronic metabolic acidosis (including diabetic ketoacidosis),History of serious hypersensitivity reaction to Janumet or its components,Use of iodinated contrast agents with e GFR <60 m L/min/1.73 m² or liver disease, alcohol abuse, or conditions altering renal function
History of serious hypersensitivity reaction to empagliflozin, linagliptin, or any excipient,Severe renal impairment (e GFR < 30 m L/min/1.73 m²), end-stage renal disease, or dialysis (empagliflozin),Type 1 diabetes mellitus (empagliflozin; risk of ketoacidosis)
Avoid excessive alcohol intake (increases risk of lactic acidosis). Take with food to minimize gastrointestinal upset. No specific food restrictions; maintain consistent carbohydrate intake for blood glucose control.
No significant food interactions. Alcohol may increase risk of lactic acidosis and ketoacidosis; limit intake. Avoid grapefruit juice as it may affect linagliptin metabolism (minor interaction, but caution advised).
Janumet (sitagliptin/metformin) is classified as FDA Pregnancy Category B for sitagliptin and Category B for metformin. Animal studies show no evidence of teratogenicity, but there are no adequate well-controlled studies in pregnant women. Risk cannot be ruled out. Metformin crosses the placenta and may cause fetal lactic acidosis in third trimester. Generally, insulin is preferred for gestational diabetes management.
Empagliflozin: Based on animal studies, empagliflozin may cause renal toxicity in the developing fetus, particularly during the second and third trimesters when fetal kidneys are maturing. Human data are limited; however, SGLT2 inhibitors are generally avoided in the second and third trimesters due to potential risk of acute kidney injury in neonates. Linagliptin: Animal studies have shown no evidence of teratogenicity at clinically relevant doses. Human data are insufficient; however, DPP-4 inhibitors are generally considered low risk during pregnancy. Overall, combination should be avoided unless clearly needed, particularly in the second and third trimesters.
Sitagliptin is excreted in rat milk; unknown in humans. Metformin is excreted into human milk at low levels with an estimated infant dose of 0.18-0.4 mg/kg/day (M/P ratio ~0.35-0.65). Due to potential for hypoglycemia and uncertain long-term effects, breastfeeding is not recommended during Janumet therapy.
Empagliflozin: Unknown if excreted in human milk; animal studies show excretion in milk. Due to potential for adverse effects on the developing infant (e.g., renal effects), breastfeeding is not recommended. Linagliptin: Unknown if excreted in human milk; animal studies show low levels in milk. Caution is advised. Both drugs: M/P ratio not available. Manufacturer recommends discontinuing drug or breastfeeding.
Janumet is not recommended during pregnancy. If used, dose adjustments may be necessary due to pregnancy-induced increased renal clearance of metformin; however, no specific guidelines exist. Renal function should be monitored closely to avoid metformin accumulation and lactic acidosis. Typically, insulin therapy is initiated.
Empagliflozin: Pregnancy alters pharmacokinetics (increased renal clearance, volume of distribution), but no specific dose adjustments are recommended due to lack of data. However, empagliflozin is contraindicated in pregnancy, particularly in the second and third trimesters. Linagliptin: No dose adjustment required based on pharmacokinetic changes in pregnancy; however, safety data are limited. Overall, alternative therapies are preferred during pregnancy.
Janumet combines sitagliptin (DPP-4 inhibitor) and metformin (biguanide). Dose adjustment required for renal impairment (e GFR <45 m L/min/1.73 m² contraindicated; <30 for metformin component). Monitor for lactic acidosis (rare but serious) especially in hypoxic states. Discontinue for 48 hours before iodinated contrast imaging with metformin component. Pancreatitis risk: monitor for persistent severe abdominal pain. Not for type 1 diabetes or ketoacidosis.
Empagliflozin/linagliptin should not be used in patients with type 1 diabetes or for diabetic ketoacidosis treatment. Assess renal function before initiation and periodically; e GFR <45 m L/min/1.73 m2 is a contraindication for empagliflozin. Monitor for signs of ketoacidosis, even if blood glucose is not markedly elevated. Linagliptin does not require dose adjustment for renal impairment. Genital mycotic infections and urinary tract infections are common with empagliflozin; counsel on hygiene. Temporary discontinuation of SGLT2 inhibitors is recommended before surgery or during prolonged fasting to reduce ketoacidosis risk.
Take with meals to reduce gastrointestinal side effects.,If you miss a dose, take it with your next meal unless the next dose is due; do not double dose.,Monitor for symptoms of pancreatitis (severe abdominal pain, nausea, vomiting) and report immediately.,Report symptoms of lactic acidosis (muscle pain, weakness, difficulty breathing, drowsiness) especially if you have kidney problems or are over 65.,Avoid alcohol while taking this medication to reduce the risk of lactic acidosis.,Stay hydrated, especially if you are sick (vomiting, diarrhea) or exercising intensely.,Check blood sugar regularly as directed; carry a source of sugar for hypoglycemia.,Tell your doctor if you are pregnant, breastfeeding, or planning surgery.
Take this medication exactly as prescribed, usually once daily with or without food.,Stay well hydrated to reduce risk of dehydration and urinary tract infections.,Report symptoms of genital itching, discomfort, or discharge promptly for possible yeast infection.,Seek immediate medical attention if you experience symptoms of ketoacidosis (nausea, vomiting, abdominal pain, confusion, unusual fatigue, difficulty breathing) even if blood sugar is normal.,Do not share this medication with others; it is not for treating type 1 diabetes.,Inform all healthcare providers that you are taking this medication, especially before surgery or procedures.
No interactions on record
"Empagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces renal glucose reabsorption, leading to decreased blood glucose levels. Rosoxacin, a quinolone antibiotic, may enhance the hypoglycemic effects of empagliflozin by potentiating insulin secretion or improving insulin sensitivity, which could increase the risk of hypoglycemic episodes, especially in patients with diabetes mellitus."
"Quinethazone, a thiazide-like diuretic, reduces intravascular volume and may blunt the osmotic diuretic effect of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, thereby decreasing empagliflozin's efficacy in lowering blood glucose. This interaction is mediated through volume contraction leading to reduced renal perfusion and diminished glucose excretion. Clinically, patients may experience higher-than-expected blood glucose levels, potentially compromising glycemic control."
"Concomitant use of lisinopril, an angiotensin-converting enzyme inhibitor, and empagliflozin, a sodium-glucose cotransporter-2 inhibitor, may enhance the risk of hypotension, acute kidney injury, and hyperkalemia. Lisinopril reduces angiotensin II-mediated vasoconstriction and aldosterone secretion, which can be compounded by empagliflozin-induced volume depletion and osmotic diuresis. This interaction is particularly concerning in patients with renal impairment or those on other medications affecting the renin-angiotensin-aldosterone system."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JANUMET vs EMPAGLIFLOZIN; LINAGLIPTIN, answered by our medical review team.
JANUMET is a DPP-4 Inhibitor/Biguanide Combination that works by Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.. EMPAGLIFLOZIN; LINAGLIPTIN is a DPP-4 Inhibitor that works by Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that prolongs the activity of incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JANUMET and EMPAGLIFLOZIN; LINAGLIPTIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JANUMET is: Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.. The standard adult dose of EMPAGLIFLOZIN; LINAGLIPTIN is: 10 mg empagliflozin/5 mg linagliptin orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JANUMET and EMPAGLIFLOZIN; LINAGLIPTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JANUMET is classified as Category C. Janumet (sitagliptin/metformin) is classified as FDA Pregnancy Category B for sitagliptin and Category B for metformin. Animal studies show no evidence of teratogenicity, but there. EMPAGLIFLOZIN; LINAGLIPTIN is classified as Category A/B. Empagliflozin: Based on animal studies, empagliflozin may cause renal toxicity in the developing fetus, particularly during the second and third trimesters when fetal kidneys are m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.